Patents by Inventor Randall F. Holcombe

Randall F. Holcombe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of detection and treatment of colon cancer
    Patent number: 7413873
    Abstract: The present invention is based, in part, on the discovery that colon carcinoma, carcinogenesis, or the predisposition thereto is associated with the level of Wnt2, Wnt5, BMP6, and Fz receptors and the full-length and dominant negative form of LEF1.
    Type: Grant
    Filed: April 25, 2002
    Date of Patent: August 19, 2008
    Assignee: The Regents of the University of California
    Inventors: Marian L. Waterman, Randall F. Holcombe, J. Lawrence Marsh, Karine Hovanes, Tony Wai Hung Li
  • Method of detection and treatment of colon cancer
    Publication number: 20020187502
    Abstract: The present invention is based, in part, on the discovery that colon carcinoma, carcinogenesis, or the predisposition thereto is associated with the level of Wnt2, Wnt5, BMP6, and Fz receptors and the full-length and dominant negative form of LEF1.
    Type: Application
    Filed: April 25, 2002
    Publication date: December 12, 2002
    Inventors: Marian L. Waterman, Randall F. Holcombe, J. Lawrence Marsh, Karine Hovanes, Tony Wai Hung Li
  • Method of detection and treatment of colon cancer by analysis of beta-catenin-sensitive isoforms of lymphoid enhancer factor-1
    Publication number: 20020169300
    Abstract: The present invention relates to the discovery that LEF1 is a new type of target gene in that it is ectopically activated in colon cancer. The pattern of this ectopic expression is unusual because it derives from selective activation of a promoter for a full-length LEF1 isoform that binds &bgr;-catenin, but not a second, intronic promoter that drives expression of a dominant negative isoform. &bgr;-catenin/TCF complexes can activate the promoter for full-length LEF1 suggesting that in cancer, high levels of these complexes misregulate transcription to favor a positive feedback loop for Wnt signaling by inducing selective expression of full length, &bgr;-catenin sensitive forms of LEF/TCFs. The invention provides diagnostic and therapeutic methodologies based on the discoveries described herein.
    Type: Application
    Filed: January 29, 2002
    Publication date: November 14, 2002
    Inventors: Marian L. Waterman, Randall F. Holcombe, J. Lawrence Marsh, Karine Hovanes, Tony Wai Hung Li